Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GDC-0917||CUDC-427||SMAC Mimetic 8||GDC-0917 is a SMAC mimetic, which acts as an antagonist to Inhibitor of Apoptosis Protein (IAP) family proteins, resulting in decreased tumor growth (PMID: 24041744).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||GDC-0917||Phase I||Actionable||In a Phase I clinical trial, GDC-0917 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 2503)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01908413||Phase I||GDC-0917||Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma||Terminated|